ACR 2019

Opioids have no impact on QoL or depression; smaller benefits seen for pain for strong versus weak opioids

Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.

Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.

Researchers studied the risk factors for relapse, including prednisolone clearance and glucocorticoid-induced transcript 1 promoter polymorphism (rs37972), in patients with giant cell arteritis.

Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.

In this post hoc analysis, researchers evaluated the efficacy and safety of abaloparatide followed by alendronate vs placebo followed by alendronate in a subgroup of patients with osteoarthritis.

Researchers evaluated the safety and efficacy of a sublingual formulation of cyclobenzaprine in fibromyalgia.

Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.

Researchers evaluated the efficacy and safety of guselkumab in patients with active psoriatic arthritis who were biologic-naive or treated with prior tumor necrosis factor inhibitors.

Researchers determined whether body mass index had any clinical impact on the efficacy of diclofenac sodium gel 1% in patients with knee osteoarthritis.